AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15213563
Drug: 2-dose intra-partum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose intra-partum nevirapine in combination with standard antiretroviral therapy
Trial: 30408810
Drug: Low-salt (LS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt (LS) diet (3.0 g/day of NaCl)
Trial: 30408810
Drug: High-salt (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt (HS) diet (18.0 g/day of NaCl)
Trial: 26526662
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 diabetes with albuminuria (≥ 30 mg/24 h)
Trial: 26526662
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 diabetes with normoalbuminuria (<30 mg/24 h)
Trial: 22103428
Drug: Tramadol-lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol-lidocaine (1 mg kg(‐1) and 2.46 mg kg(‐1))
Trial: 20602575
Drug: exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise plus paroxetine 40 mg/day (n=21)
Trial: 20602575
Drug: exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise plus pill placebo (n=20)
Trial: 19952830
Drug: Water trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water trial (500 mL of plain water)
Trial: 19952830
Drug: Bar trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar trial (commercially available energy bar with 10 µg of 19‐norandrostenedione)
Trial: 18410769
Drug: aP (acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aP (acellular pertussis vaccine)
Trial: 18410769
Drug: HBV (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV (hepatitis B vaccine)
Trial: 20064838
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group received counseling, nicotine patches, quit guide, plus information about cigarette characteristics
Trial: 20064838
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received counseling, nicotine patches, quit smoking guide
Trial: 26015558
Drug: Behavioral Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Family Systems Therapy for Diabetes (BFST‐D)
Trial: 12698207
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (10 mg daily)
Trial: 9925870
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment with porcine surfactant (Curosurf)
Trial: 8781630
Drug: Oral thyrotrophin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thyrotrophin-releasing hormone (TRH) and placebo
Trial: 29479010
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target of < 2.07 mmol/L
Trial: 20228381
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 or 100 mg)
Trial: 12148173
Drug: Triamcinolone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (200 mcg twice daily)
Trial: 2015731
Drug: Fluconazole, 200
RxNorm normalized name: Fluconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 200 mg orally, daily for 14 days
Trial: 7278648
Drug: Mazindol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (1 mg, TID, po)
Trial: 26743237
Drug: Delayed ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed ventricular tachycardia therapy programming (Arm C)
Trial: 18767129
Drug: Combination recruitment
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination recruitment (both reactive and proactive)
Trial: 17660602
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF, or filgrastim) 300 mcg s/c weekly
Trial: 10533795
Drug: UDCA (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (600 mg/day)
Trial: 3524728
Drug: Sulphamethoxazole 2
RxNorm normalized name: Sulphamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphamethoxazole 2 g daily for 3 months
Trial: 25230733
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin combined with Tiao Jing Cu Yun pills
Trial: 22169113
Drug: MBX-8025 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-8025 (50 mg/d)
Trial: 22169113
Drug: MBX-8025 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-8025 (100 mg/d)
Trial: 17942379
Drug: Therapies evaluated
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies evaluated in trials
Trial: 24195872
Drug: APAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP treatment for 2 or 3 preoperative nights and 5 postoperative nights.
Trial: 21208974
Drug: RLY5016 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLY5016 (30 g/day)
Trial: 31895058
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based treatment
Trial: 31895058
Drug: Cognitive-behavioral usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral usual treatment
Trial: 21429226
Drug: Non-professional mentor
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-professional mentor support (weekly home visiting for 12 months)
Trial: 19646193
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (600 mg/day)
Trial: 7530821
Drug: Oxy‐ or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy‐ or xylometazoline nasal spray for 30 days
Trial: 3284831
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg piretanide once or twice daily
Trial: 3294616
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride once daily
Trial: 28716617
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy (DT) and Waitlist Dignity Therapy (WDT)
Trial: 25801893
Drug: Intensive regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive regimen (IR) of cholecalcipherol (300,000 UI initial bolus followed by 50,000 UI monthly)
Trial: 25801893
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (SR) of cholecalcipherol (25,000 UI monthly)
Trial: 24061864
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered at 6:00
Trial: 26093951
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered at 18:00
Trial: 21568083
Drug: CCHT 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCHT 2 mg estradiol plus 1 mg norethisteron acetate
Trial: 10662566
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine (PVP-I) in scrub formulation followed by alcoholic PVP-I
Trial: 10662566
Drug: Chlorhexidine in
RxNorm normalized name: Product containing chlorhexidine in dental dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine in scrub formulation followed by alcoholic chlorhexidine
Trial: 9305480
Drug: Amoxycillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1 mg b.d.) + Omeprazole (20 mg b.d.)
Trial: 9305480
Drug: Amoxycillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1 mg b.d.) + Lansoprazole (30 mg b.d.)
Trial: 9305480
Drug: Amoxycillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (1 mg b.d.) + Ranitidine (300 mg b.d.)
Trial: 10899382
Drug: Mecamylamine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 5 mg
Trial: 10899382
Drug: Mecamylamine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 10 mg
Trial: 1410163
Drug: Mecamylamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (all doses)
Trial: 3931138
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine at 2 mg every 2 hours
Trial: 3931138
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine at lower doses
Trial: 14999611
Drug: T-1249 monotherapy
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-1249 monotherapy (subcutaneous injection) at doses ranging from 6.25 to 192 mg/day for 14 days
Trial: 9839758
Drug: Donepezil 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 4.0 mg
Trial: 9839758
Drug: Donepezil 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 6.0 mg
Trial: 21625083
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of hemodialysis at an estimated glomerular filtration rate (eGFR) of 5‐7 ml/min
Trial: 10685792
Drug: Cyclosporine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (2.5 to 4 mg/kg/day) plus MTX
Trial: 8088933
Drug: Heparan sulfate
RxNorm normalized name: heparan sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparan sulfate pharmacodynamics identification programme using a personal computer
Trial: 3537785
Drug: Low-dose ketoconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ketoconazole, 100 mg daily for six months (Group C)
Trial: 3537785
Drug: Low-dose ketoconazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketoconazole (Group C)
Trial: 27380603
Drug: Ditto Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ditto Preparation and Distraction
Trial: 17347975
Drug: i.v. L-propionyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. L-propionyl carnitine treatment for two months
Trial: 12663237
Drug: Propranolol 40-120
RxNorm normalized name: propranolol hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40-120 mg/day
Trial: 8290486
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (V/Z)
Trial: 3728581
Drug: 100 gm
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 gm of oral glucose (group G)
Trial: 26957102
Drug: Intravenous Patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Patient Controlled Analgesia (IV-PCA)
Trial: 11199951
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with cognitive behavioral therapy
Trial: 24399553
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg, 2 per day) with cognitive behavioral therapy
Trial: 18436195
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 1 g orally twice daily (b.i.d.)
Trial: 1642682
Drug: Soluble ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble ibuprofen 200 mg sachets
Trial: 1642682
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg tablets
Trial: 1642682
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg tablets
Trial: 12045491
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg
Trial: 30977033
Drug: ADV 10
RxNorm normalized name: ADV-TK
DrugBank: Aglatimagene besadenovec (DB15074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV 10 mg
Trial: 19580713
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue spray applied to the axillary fossa in 45 patients
Trial: 19580713
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in 45 patients
Trial: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
RxNorm normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-hydroxy-camptothecin (10-HCPT) 10 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Trial: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
RxNorm normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-hydroxy-camptothecin (10-HCPT) 12 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Trial: 17785082
Drug: 10-hydroxy-camptothecin (10-HCPT)
RxNorm normalized name: 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-hydroxy-camptothecin (10-HCPT) 8 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Trial: 9535618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitrate therapy)
Trial: 6683976
Drug: Rectal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal absorption from aqueous solution
Trial: 6683976
Drug: Rectal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal absorption from fatty suppository
Trial: 6683976
Drug: Rectal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal absorption from alkaline solution containing codeine phosphate
Trial: 6683976
Drug: Various rectal
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various rectal dosage forms
Trial: 21613389
Drug: Computer-delivered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-delivered treatment (CDT)
Trial: 19892281
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (NTG)
Trial: 16636488
Drug: valsartan plus
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: valsartan plus ACE inhibitor
Trial: 10560360
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg, twice daily
Trial: 10560360
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg, twice daily
Trial: 2069791
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg or 180 mg twice daily
Trial: 2069791
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg twice daily
Trial: 2069791
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg twice daily
Trial: 6840169
Drug: Sobrerol (mucolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sobrerol (mucolytic drug)
Trial: 31595433
Drug: Ophthalmic 0.3%
RxNorm normalized name: ofloxacin ophthalmic 0.3% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic 0.3% gentamicin topical solution nightly for a 3-month period
Trial: 21639808
Drug: vemurafenib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vemurafenib (960 mg orally twice daily)
Trial: 24508103
Drug: dacarbazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dacarbazine (1000 mg/m² IV every 3 weeks)
Trial: 20920276
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy with capecitabine (825 mg/m² twice daily during radiotherapy)
Trial: 20920276
Drug: Preoperative combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined therapy
Trial: 18547150
Drug: 0.6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 18547150
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 18547150
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 15814754
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of ropivacaine 0.5%
Trial: 15814754
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of ropivacaine 0.5%
Trial: 15814754
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of ropivacaine 0.5%
Trial: 12432177
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CM; 0.3 g kg d 1 + 20 g Polycose)
Trial: 8613890
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (15 g dietary fiber)
Trial: 26036554
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg) via patient-controlled epidural analgesia (PCEA)
Trial: 9715842
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin (40 mg/m2 every 2 weeks)
Trial: 11099365
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (0.45% NaCl) equal to 50% of prior dehydration
Trial: 2908820
Drug: ICI 118,551,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551, 50 mg t.i.d.
Trial: 2880804
Drug: Propranolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80 mg t.i.d.
Trial: 31444314
Drug: Collagen-containing supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-containing supplements (gelatin 20 g and hydrolyzed collagen 20 g)
Trial: 31444314
Drug: Dairy protein
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy protein supplements (calcium caseinate 20 g and hydrolyzed casein 20 g)
Trial: 28981381
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (180 mg EPA, 120 mg DHA) supplementation (1 g/day for 4 weeks)
Trial: 23338256
Drug: 1% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% NaOCl solution
Trial: 12398236
Drug: Hypoglycemic agents
RxNorm normalized name: HYPOGLYCEMIC AGENTS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic agents and/or diet
Trial: 9884259
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir vs. ganciclovir in D-R+ patients
Trial: 416989
Drug: Lactobacilli preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli preparation (Lactinex)
Trial: 30506495
Drug: NESP® (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NESP® (reference formulation)
Trial: 27138652
Drug: Oritavancin 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oritavancin 1600 mg IV over 3 hours
Trial: 25681068
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg oral
Trial: 24321697
Drug: Coping with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping with negative affect as a target in treatments for marijuana dependence
Trial: 7729296
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral magnesium therapy (30 mmol/day)
Trial: 2200300
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered at a temperature of 4 degrees C
Trial: 2200300
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered at standard temperature (not specified)
Trial: 9243749
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B surface antigen vaccine
Trial: 30519818
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg, three times a day for 5 days)
Trial: 25293351
Drug: DHA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (400 mg daily)
Trial: 17071935
Drug: GV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV plus CDDP 50 mg/m(2) on days 1 and 8 (PGV arm)
Trial: 17071935
Drug: GT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT plus CDDP 50 mg/m(2) on days 1 and 8 (PGT arm)